About Clinical Trials

Hundreds of clinical trials throughout the United States are currently being held to evaluate immunotherapy drugs as new treatments for melanoma, in combination with other strategies or as new uses for existing treatments. New participants are needed for these studies to succeed, but many patients are fearful of participating in clinical trials. Health care professionals can be instrumental in influencing and encouraging patient participation.

Encourage Patients to Try Clinical Trials

Offer these reasons for why a patient should consider participating in a clinical trial:Tip.jpg

  1. A clinical trial may offer a worthwhile alternative to a treatment that is not working as well as expected.
  2. A clinical trial may significantly improve the patient’s quality of life. Discuss the advantages and disadvantages of participating, especially addressing any concerns about side effects.
  3. Tell patients they will not only help identify treatments that work, they’ll help eliminate those that don’t. Patients likely don’t realize the integral role they play in helping refine and improve the way millions of people with all types and stages of melanoma are treated.
  4. Educate them about how treatments become approved by the U.S. Food and Drug Administration by telling them every treatment available today went through clinical trials to get FDA approval.
  5. Assure your patients that they will be treated with dignity and respect and will receive the highest quality of care for melanoma.

Getting Started

To be eligible for an immunotherapy clinical trial, a patient must have a properly functioning immune system. In addition, the patient must meet certain eligibility criteria (cancer type, overall health, treatment history, etc.).

Current clinical trials using immunotherapy for melanoma with open recruitment as of September 16, 2016, are displayed in the Immunotherapy for the Treatment of Melanoma for Health Care Professionals. Each trial listed is categorized as “cancer immunotherapy” on www.clinicaltrials.gov.

Encourage patients to keep researching available trials, especially if they locate a clinical trial that is not recruiting in their area. Remind them that new studies and new phases are happening all the time.

Share this information with your patient and explain how to learn about a specific trial with these instructions:

[1] Visit www.clinicaltrials.gov.  [2] Enter the trial record number into the search box located at the top of the Web page. The trial record number is a unique identification code assigned to each clinical study.  [3] The trial will be “Recruiting” or “Not yet recruiting,” which means the studies are either actively looking for participants or getting ready to look for participants.

©Patient Resource

Open Forum Discussions

  • Hello, We're excited to announce the upcoming meeting "New Frontiers in Cancer immunotherapy", presented by the Irish Society for Immunology (ISI) and the Society for Immunotherapy of ...

  • Hello! Attached are two flyers for the fourth Targets for Cancer IO: Deep Dive Series . The first flyer is for tomorrow's Personalized Vaccines webinar that will be held from ...

  • Hello! Attached are flyers for the Deep Dive Webinar Series and the Computational Immuno-oncology Webinar Series . Please share both with any colleagues that may be interested in ...

  • Hello, As fellow community members, I'm excited to share with you that SITC recently launched 2024 fellowships with $340,000 in available funding to advance cancer immunotherapy research. ...

  • Hello! There's less than two weeks left to save on Early Registration & Housing for the 2024 SITC Spring Scientific , Metabolism at the Hub of Cancer and Immunity. The Spring Scientific ...

SITC Resources

12-12-2022 10:54
This is the library for the Enduring Materials from the Targets for Cancer IO: A Deep Dive, TCR based therapies webinar that was conducted on December 7, 2022 . Date of Live Event: Wednesday, Dec. 7, 2022 – 2 p.m.–4 p.m. CST Moderators: Harlan Robins, PhD – Adaptive Biotechnologies ...
11-01-2022 13:02
On October 28, 2022, leading experts from the SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel presented "Case Studies in Immunotherapy for the Treatment of Nonmelanoma Skin Cancer – SITC CPG Webinar." This high-level webinar included case studies that illustrated execution of the Clinical ...
10-04-2022 12:12
On October 3, 2022, leading experts from the SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel presented "Practical Management Pearls for Immunotherapy for the Treatment of Nonmelanoma Skin Cancer — SITC CPG Webinar." This high-level webinar was designed to teach attendees how to appraise ...
10-04-2022 12:04
Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat successfully. ...
09-28-2022 16:04
This is the library for the Enduring Materials from the Targets for Cancer IO: A Deep Dive, iPSC derived cell therapies webinar that was conducted on September 26, 2022 . Moderators: Kalle Malmberg, MD, PhD - Oslo University Hospital Jeffrey S. Miller, MD - University of Minne ...
08-26-2022 08:04
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination ...